Bausch Health Companies (NYSE:BHC) received a $32.00 target price from equities research analysts at Cantor Fitzgerald in a research note issued on Friday, May 31st, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 28.00% from the stock’s previous close.
BHC has been the subject of a number of other reports. Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Thursday, February 14th. HC Wainwright reiterated a “buy” rating on shares of Bausch Health Companies in a report on Thursday, February 28th. SunTrust Banks assumed coverage on Bausch Health Companies in a report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective for the company. Mizuho increased their price objective on Bausch Health Companies from $39.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Piper Jaffray Companies set a $28.00 price target on Bausch Health Companies and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $27.65.
Shares of BHC traded up $0.62 during trading hours on Friday, hitting $25.00. 5,757,831 shares of the stock traded hands, compared to its average volume of 4,149,300. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61. Bausch Health Companies has a 1-year low of $17.20 and a 1-year high of $28.45. The stock has a market capitalization of $8.64 billion, a price-to-earnings ratio of 6.22, a PEG ratio of 0.53 and a beta of 0.61. The firm has a fifty day simple moving average of $23.18.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Monday, May 6th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.14. The business had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm’s revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.89 earnings per share. As a group, equities research analysts expect that Bausch Health Companies will post 4.19 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BHC. Orbimed Advisors LLC increased its stake in shares of Bausch Health Companies by 89.1% during the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after purchasing an additional 1,696,400 shares during the period. Financial Sense Advisors Inc. increased its stake in shares of Bausch Health Companies by 7.7% during the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock worth $1,556,000 after purchasing an additional 6,050 shares during the period. Bank of Nova Scotia increased its stake in Bausch Health Companies by 14.6% during the 4th quarter. Bank of Nova Scotia now owns 1,207,147 shares of the company’s stock worth $22,296,000 after acquiring an additional 154,143 shares during the period. Greatmark Investment Partners Inc. increased its stake in Bausch Health Companies by 24.2% during the 4th quarter. Greatmark Investment Partners Inc. now owns 18,225 shares of the company’s stock worth $337,000 after acquiring an additional 3,550 shares during the period. Finally, Bessemer Group Inc. bought a new position in Bausch Health Companies during the 4th quarter worth $33,000. 53.67% of the stock is owned by institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
See Also: Quiet Period Expirations Explained
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.